Corporate Snapshot: Ebos (EBO.AX) Performance Overview
During the 24‑hour trading window concluding at 01:51 AM Central Europe on Thursday, 22 October 2026, Ebos Group Limited (ticker EBO.AX) advanced modestly by 0.12 %, reflecting a slight uptick in investor confidence. At the close of that period, a single share of Ebos was priced at approximately AUD 17.20 on major Australian exchanges.
Market Metrics
- Outstanding Shares: 209.1 million
- Market Capitalisation: AUD 3.4 billion
- Volume (last 24 hrs): About AUD 1.1 million worth of shares exchanged
- Year‑to‑Date Gain: 2.07 % since the end of the previous month
- 200‑Day Simple Moving Average (SMA): AUD 18.23
- 52‑Week Range:
- High: AUD 26.00 (17 November 2025)
- Low: AUD 14.87 (5 October 2026)
Comparative Performance
The following table summarizes the recent 24‑hour performance of peer companies within the same exchange segment:
| Stock | 24‑Hour Move | Current Price (AUD) | Market Cap (AUD) | P/E Ratio |
|---|---|---|---|---|
| Megaport (MP1.AX) | –3.26 % | 16.41 | 3.8 bn | — |
| Nib (NHF.AX) | +0.61 % | 6.60 | 3.2 bn | 17.3 |
| Pinnacle Investment Management (PNI.AX) | –0.83 % | 14.41 | 3.4 bn | 18.12 |
| Metcash (MTS.AX) | –0.63 % | 3.17 | 3.5 bn | 12.41 |
| Paladin Energy (PDN.AX) | –0.96 % | 7.37 | 3.3 bn | 416.74 |
While Ebos has edged slightly higher, most peers have experienced modest declines, suggesting a broader market pullback or sector‑specific headwinds.
Business Context
Ebos Group Limited, headquartered in Docklands, Australia, is a prominent provider of medical consumables and equipment across New Zealand and Australia. Its portfolio spans diagnostic instruments, surgical tools, prosthetics, feminine protection, anaesthetic devices, and a range of consumer products tailored to hospital and primary‑care settings. The company’s operations are integral to the supply chain that supports healthcare delivery in both countries.
Investors should note that, although the company’s share price remains within a healthy range relative to its 52‑week low, the relatively narrow 200‑day SMA indicates that price momentum may still be developing. The modest intraday volatility, coupled with a stable market capitalisation, suggests that Ebos remains a steady, if not high‑growth, participant in the healthcare distribution sector.
For more detailed information on product lines and corporate developments, the company maintains an online presence at www.ebos.co.nz .
